Latest news about Sanofi Consumer Healthcare
Sanofi Consumer Healthcare
4,648.50
-119.20(-2.50%)
Company Performance:
View Company Insights1D-2.50%
1M+3.77%
6M+0.13%
1Y-6.25%
5Y-5.20%
More news about Sanofi Consumer Healthcare
26Mar 26
Sanofi Consumer Healthcare makes institutional investor meet video recording available
Sanofi Consumer Healthcare India Limited has made the video recording of its institutional investor meet available on the company website following the March 24, 2026 Mumbai event. The company formally communicated this to BSE and NSE under SEBI Regulation 30, with Company Secretary Nikunj Kumar Savaliya handling the compliance documentation on March 26, 2026.
24Mar 26
Sanofi Consumer Healthcare India Limited Publishes Postal Ballot Notice in Newspapers
Sanofi Consumer Healthcare India Limited has published its postal ballot notice in Business Standard and Sakal newspapers on March 24, 2026, confirming dispatch to shareholders. The company seeks approval for four ordinary resolutions including material related party transactions with Opella Healthcare entities worth ₹4,614 million and remuneration matters for Non-Executive Directors and Managing Director incentive plan participation.
01Mar 26
Sanofi Consumer Healthcare India Submits Annual Secretarial Compliance Report for FY 2025
Sanofi Consumer Healthcare India Limited submitted its Annual Secretarial Compliance Report for FY ended 31st December 2025, prepared by BNP & Associates, confirming full compliance with all SEBI regulations including substantial acquisition rules, insider trading prohibitions, listing obligations, and depositories regulations. The company achieved 100% compliance across 13 key regulatory areas with no violations, deviations, or regulatory actions reported during the review period.
27Feb 26
Sanofi Consumer Healthcare India Reports Strong Q4 FY25 Performance with 45.48% Revenue Growth
Sanofi Consumer Healthcare India Limited reported strong Q4 FY25 results with total income growing 45.48% to ₹2,556 million and net profit increasing 50.11% to ₹665 million year-on-year. For FY25, the company achieved total income of ₹8,968 million, up 21.61% from the previous year, with net profit rising 32.65% to ₹2,401 million. The Board recommended a final dividend of ₹75 per equity share, reflecting robust financial performance and shareholder value creation.
26Feb 26
Sanofi Consumer Healthcare Reports Strong Q3 Performance with 50% Profit Growth
Sanofi Consumer Healthcare reported exceptional Q3 financial performance with net profit surging 50% to ₹665 million from ₹443 million year-on-year. Revenue grew significantly by 47% to ₹2.5 billion, while EBITDA increased 44.61% to ₹898 million, though EBITDA margin contracted slightly to 35.78% from 36.38%.
25Feb 26
Sanofi Consumer Healthcare India Designates Two Directors as Senior Management Personnel
Sanofi Consumer Healthcare India Limited's board designated two senior executives as Senior Management Personnel on February 25, 2026. Ms. Nupur Gurbaxani, Director of Brand & Innovation, and Mr. Viral Shah, Director of External Manufacturing, were appointed following Nomination & Remuneration Committee recommendations, with formal regulatory disclosures made to BSE and NSE.
20Feb 26
Sanofi Consumer Healthcare India Limited Schedules Board Meeting for February 25, 2026 to Consider Dividend Recommendation
Sanofi Consumer Healthcare India Limited has scheduled its Board of Directors meeting for February 25, 2026, to consider dividend recommendations for FY25 ended December 31, 2025, in addition to approving audited financial statements. The company has notified BSE and NSE in compliance with SEBI regulations, with the communication signed by Company Secretary Nikunj Kumar Savaliya on February 20, 2026.
13Nov 25
Sanofi Consumer Healthcare India Reports Strong Q3 Results with 46% Revenue Growth
Sanofi Consumer Healthcare India Limited announced strong Q3 results with revenue up 46% to ₹2,339.00 million and net profit increasing 40% to ₹629.00 million. Domestic sales grew 20% while export sales surged over 1000%. The company successfully relaunched all previously recalled products, including Depura Adult, Combiflam Suspension, Allegra Suspension, and Depura Kids. For the nine-month period, revenue grew 13% to ₹6,274.00 million with net profit up 27% to ₹1,736.00 million. The company's portfolio includes brands like Allegra, DePURA, Avil, and Combiflam in categories such as Allergy, Digestive Wellness, Pain Care, and Multivitamins.
16Oct 25
Sanofi Consumer Healthcare India Appoints Richard D'souza as CFO
Sanofi Consumer Healthcare India Limited has appointed Richard D'souza as its new Chief Financial Officer, effective October 16, 2025. D'souza brings over 25 years of leadership experience in finance, with expertise in financial strategy, M&A, investor relations, governance, and digital transformation. He previously served as Head of Finance at Bajaj Consumer Care and has experience in multinational and listed organizations in the FMCG and consumer goods sectors. The appointment aims to strengthen Sanofi's financial leadership and drive future growth.
10Oct 25
Sanofi Consumer Healthcare India CFO Narahari Naidu to Step Down
Narahari Naidu, CFO of Sanofi Consumer Healthcare India Limited, has resigned effective October 15, 2025, to pursue new career opportunities. The company has notified the BSE and NSE in compliance with SEBI regulations. Naidu expressed gratitude in his resignation email. No successor has been announced yet.
04Aug 25
Sanofi Consumer Healthcare India Appoints New CFO Amid Strong Q2 Performance
Sanofi Consumer Healthcare India has appointed Mr. Narahari Naidu as CFO effective August 4th, 2025. The company reported impressive Q2 2025 results with revenue at ₹2,209.00 million, up 28.21% YoY, and net profit at ₹607.00 million, a 109.31% increase from Q2 2024. The company successfully relaunched Depura Adult and Combiflam Suspension, contributing to strong performance. An exceptional gain of ₹66.00 million was recorded from reversing excess demerger-related provisions.
04Aug 25
Sanofi Consumer Healthcare India Reports Strong Q1 Results with 28% Revenue Growth
Sanofi Consumer Healthcare India Limited reported impressive Q1 financial results. Revenue from operations increased by 28% to ₹2,209.00 million, while net profit surged by 109% to ₹607.00 million compared to the previous year. Total income rose by 31% to ₹2,265.00 million. The company successfully relaunched Combiflam Suspension and is working on bringing back other recalled products. An exceptional gain of ₹66.00 million was recorded from reversing excess demerger-related provisions. The Board approved the appointment of Mr. Narahari Naidu as the new Chief Financial Officer.
02May 25
Sanofi Consumer Healthcare India Reports Mixed Q4 Results Amid Product Recalls
Sanofi Consumer Healthcare India Limited (SCHIL) released Q4 2025 results, showing revenue decline but improved profitability. Revenue dropped 22% YoY to ₹1,726.00 crore due to product recalls. Net profit fell 20.3% YoY to ₹500.00 crore but increased sequentially. EBITDA decreased to ₹640.00 crore, while EBITDA margin slightly improved to 37.08%. The company has completed most product recalls and relaunched Depura Adult. Management remains focused on bringing back other key products and improving market position.
25Apr 25
Sanofi Consumer Healthcare Faces Potential 26% Stake Acquisition by Opal Bidco Sas and Clayton, Dubilier & Rice Fund
Opal Bidco Sas, with Clayton, Dubilier & Rice Fund XII, L.P., has announced an open offer to acquire up to 26% stake (59,87,962 equity shares) in Sanofi Consumer Healthcare India Limited. The offer, made to public shareholders, complies with SEBI regulations. Key dates include the public announcement on October 21, 2024, and the final letter of offer issuance on April 12, 2025. This potential ownership shift could significantly impact the company's strategic direction and the Indian pharmaceutical market.
24Apr 25
Opal Bidco SAS Proposes 26% Stake Acquisition in Sanofi Consumer Healthcare India
Opal Bidco SAS, in association with Clayton, Dubilier & Rice Fund, has announced an open offer to acquire a 26% stake (59,87,962 equity shares) in Sanofi Consumer Healthcare India Limited. The offer timeline spans from October 21, 2024, to April 24, 2025, with key events including public announcements, detailed statements, and letter of offer issuance. This move could potentially impact the company's strategic direction and operations, and is being conducted in compliance with SEBI regulations.
20Feb 25
Sanofi Consumer Healthcare Declares ₹55 Dividend, Reports Strong FY2024 Performance
Sanofi Consumer Healthcare India Limited (SCHIL) has declared a final dividend of ₹55 per equity share for FY2024, subject to shareholder approval. The company reported total income of ₹7,375 million and net profit of ₹1,810 million for the year ended December 31, 2024. Revenue from operations grew by 30.4% to ₹7,245 million. SCHIL completed its demerger from Sanofi India Limited and listed on NSE and BSE in September 2024. The company voluntarily recalled Allegra and Combiflam Suspensions in July 2024 as a precautionary measure.
20Feb 25
Sanofi Consumer Healthcare: Q4 Profit Drops 35%, Declares ₹55 Dividend
Sanofi Consumer Healthcare India Limited (SCHIL) reported a significant downturn in its Q4 2024 financial results. Revenue decreased by 24% to ₹170.7 crore, while net profit fell by 34.8% to ₹44.3 crore compared to Q4 2023. EBITDA also declined by 30.6% to ₹61.1 crore, with margins contracting to 36.4%. Despite the challenging quarter, the company declared a final dividend of ₹55 per share for FY2024, subject to shareholder approval.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Dr Reddys Laboratories
Cipla
Lupin
Mankind Pharma
Zydus Life Science
Aurobindo Pharma
Laurus Labs
1,880.00
(+1.74%)
6,736.50
(+0.39%)
4,542.70
(+3.70%)
1,286.30
(-0.59%)
1,308.00
(-2.90%)
2,267.00
(-4.73%)
2,465.10
(+1.41%)
953.60
(+1.44%)
1,491.70
(+0.30%)
1,270.50
(+3.44%)
Get More Market Insights with
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
